Pioglitazone Hydrochloride (CAS 112529-15-4) — formula C19H20N2O3S, molecular weight 356.4; category organic chemicals.
| CAS Number | 112529-15-4 |
|---|---|
| Molecular Formula | C19H20N2O3S |
| Molecular Weight | 356.4 |
| Melting Point | 193-194C |
| LogP | 2.3 |
| Applications | Uses: Hypoglycemic Agents, MEDICATION, Use (kg, approx.) in Germany (2009): >1000, Use (kg) in USA (2002): 7540, Consumption (g per capita, approx.) in Germany (2009): 0.0122, Consumption (g per capita) in the USA (2002): 0.0267, Excretion rate: 0.2, Calculated removal (%): 44.8, Treatment of Type II diabetes mellitus, Methods of Manufacturing: Pioglitazone exists in two polymorphic crystal forms. Polymorph 1 is used in the manufacture of the finished drug product. The manufacture of pioglitazone consists of six steps, the last in combination with hydrochloride to yield pioglitazone hydrochloride., Preparation: K. Meguro, T. Fujita, European Patent Office patent 193256, eidem United States of America patent 4687777 (1986, 1987 both to Takeda), Formulations, Preparations: Table: Pioglitazone Hydrochloride Combinations [Table#6912], Table: Pioglitazone Hydrochloride Combinations [Table#6913], General Manufacturing Information: Information available in 2005 indicated that Piaglitazone was used in the manufacture of pharmaceutical preparations in the following countries: India, Spain, Thailand (1) Information available in 2005 indicated that Piaglitazone hydrochloride was used in the manufacture of pharmaceutical preparations in the following countries: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, India, Italy, Japan, Mexico, New Zealand, Norway, Portugal, Romania, South Africa, Sweden, Switzerland, Thailand, United Kingdom, United States (1, 2), Pioglitazone Hydrochloride |
| Category | Organic Chemicals |
Documented applications: Uses: Hypoglycemic Agents, MEDICATION, Use (kg, approx.) in Germany (2009): >1000, Use (kg) in USA (2002): 7540, Consumption (g per capita, approx.) in Germany (2009): 0.0122, Consumption (g per capita) in the USA (2002): 0.0267, Excretion rate: 0.2, Calculated removal (%): 44.8, Treatment of Type II diabetes mellitus, Methods of Manufacturing: Pioglitazone exists in two polymorphic crystal forms. Polymorph 1 is used in the manufacture of the finished drug product. The manufacture of pioglitazone consists of six steps, the last in combination with hydrochloride to yield pioglitazone hydrochloride., Preparation: K. Meguro, T. Fujita, European Patent Office patent 193256, eidem United States of America patent 4687777 (1986, 1987 both to Takeda), Formulations, Preparations: Table: Pioglitazone Hydrochloride Combinations [Table#6912], Table: Pioglitazone Hydrochloride Combinations [Table#6913], General Manufacturing Information: Information available in 2005 indicated that Piaglitazone was used in the manufacture of pharmaceutical preparations in the following countries: India, Spain, Thailand (1) Information available in 2005 indicated that Piaglitazone hydrochloride was used in the manufacture of pharmaceutical preparations in the following countries: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, India, Italy, Japan, Mexico, New Zealand, Norway, Portugal, Romania, South Africa, Sweden, Switzerland, Thailand, United Kingdom, United States (1, 2), Pioglitazone Hydrochloride.
Pioglitazone Hydrochloride is a carbon-based organic compound with CAS registry number 112529-15-4 and molecular formula C19H20N2O3S (molecular weight 356.4), belonging to the organic chemicals segment of chemical raw materials.
CAS number: 112529-15-4
Its molecular formula C19H20N2O3S comprises 19 C, 20 H, 2 N, 3 O, 1 S atoms.
Also known as: Pioglitazone Hydrochloride · 盐酸吡格列酮
Category: organic chemicals
The CAS registry number of Pioglitazone Hydrochloride is 112529-15-4.
Molecular formula C19H20N2O3S, molecular weight 356.4.
It is also registered under: Pioglitazone Hydrochloride, 盐酸吡格列酮.
Recorded applications: Uses: Hypoglycemic Agents, MEDICATION, Use (kg, approx.) in Germany (2009): >1000, Use (kg) in USA (2002): 7540, Consumption (g per capita, approx.) in Germany (2009): 0.0122, Consumption (g per capita) in the USA (2002): 0.0267, Excretion rate: 0.2, Calculated removal (%): 44.8, Treatment of Type II diabetes mellitus, Methods of Manufacturing: Pioglitazone exists in two polymorphic crystal forms. Polymorph 1 is used in the manufacture of the finished drug product. The manufacture of pioglitazone consists of six steps, the last in combination with hydrochloride to yield pioglitazone hydrochloride., Preparation: K. Meguro, T. Fujita, European Patent Office patent 193256, eidem United States of America patent 4687777 (1986, 1987 both to Takeda), Formulations, Preparations: Table: Pioglitazone Hydrochloride Combinations [Table#6912], Table: Pioglitazone Hydrochloride Combinations [Table#6913], General Manufacturing Information: Information available in 2005 indicated that Piaglitazone was used in the manufacture of pharmaceutical preparations in the following countries: India, Spain, Thailand (1) Information available in 2005 indicated that Piaglitazone hydrochloride was used in the manufacture of pharmaceutical preparations in the following countries: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, India, Italy, Japan, Mexico, New Zealand, Norway, Portugal, Romania, South Africa, Sweden, Switzerland, Thailand, United Kingdom, United States (1, 2), Pioglitazone Hydrochloride.
Category: Organic Chemicals.
Independent reference data for Pioglitazone Hydrochloride (CAS 112529-15-4), compiled from public chemistry databases.
| CAS Registry Number | 112529-15-4 |
|---|---|
| PubChem CID | 4829 |
| Molecular formula | C19H20N2O3S |
| IUPAC name | 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
| UNII (FDA) | X4OV71U42S |
| Molecular Weight | 356.4 |
|---|---|
| XLogP3 | 3.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 7 |
| Exact Mass | 356.11946368 |
| Monoisotopic Mass | 356.11946368 |
| Topological Polar Surface Area | 93.6 |
| Heavy Atom Count | 25 |
| Melting Point | 193-194C |
|---|---|
| Melting Point | 183-184 °C |
| Melting Point | 183 - 184 °C |
| Solubility | 4.42e-03 g/L |
| LogP | 2.3 |
| LogP | 3.39 |
| Dissociation Constants | 5.19 |
Pioglitazone; 111025-46-8; Glustin; Zactos; Pioglitazona; Pioglitazonum; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; AD-4833; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; CHEBI:8228; X4OV71U42S; U-72107; 5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; 5-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE; DTXCID1017129; DTXSID3037129
| Reported hazard statements | H302, H312, H332 (16.7%), H315 (16.7%), H319 (16.7%), H335 (16.7%), H351 (16.7%) |
|---|
H302+H312+H332 (16.7%): Harmful if swallowed, in contact with skin or if inhaled [Warning Acute toxicity, oral; acute toxicity, dermal; acute toxicity, inhalation]
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
Pioglitazone Hydrochloride · CAS 112529-15-4 · C19H20N2O3S. UNII X4OV71U42S. Melting Point: 193-194C; Melting Point: 183-184 °C; Melting Point: 183 - 184 °C.
Source: PubChem / Wikidata; the batch COA governs where values differ.
Supplier: Jinan Shenghe Chemical Co., Ltd.
中文页面: 盐酸吡格列酮